Symposium 1
Symposium 2
Symposium 3
Symposium 4
Oral Presentation 1
Symposium 5
IHA-KSoLA Joint Symposium
Symposium 6
Symposium 7
JAS-KSoLA Joint Symposium
Symposium 8
Symposium 9
Breakfast Symposium 1 (K+E)
Breakfast Symposium 2
Breakfast Symposium 3
Breakfast Symposium 4
Oral Presentation 2
Symposium 10
Symposium 11
Symposium 12
Plenary Lecture 1
Special Lecture (K)
Luncheon Symposium 1 (K)
Luncheon Symposium 2
Luncheon Symposium 3
Luncheon Symposium 4 (K)
Luncheon Symposium 5
Symposium 13
Symposium 14
Symposium 15
VAS-KSoLA Joint Symposium
Symposium 16
Symposium 17
Plenary Lecture 2
Symposium 18
Symposium 19
Symposium 20
Symposium 21
Breakfast Symposium 5
Breakfast Symposium 6
Breakfast Symposium 7
Breakfast Symposium 8
Oral Presentation 3
TSLA-KSoLA Joint Symposium
Symposium 22
MSA-KSoLA Joint Symposium
Plenary Lecture 3
Plenary Lecture 4
Luncheon Symposium 6 (K)
Luncheon Symposium 7
Luncheon Symposium 8
Symposium 23
Symposium 24
Symposium 25
Symposium 26
Symposium 27
Symposium 28
Symposium 29
Symposium 30
EAS-KSoLA Joint Symposium
Symposium 31
Symposium 32
09. 10(Thu)
09. 10(Thu) 13:00~14:30 Room 1
Nutritional Immunometabolism in Atherosclerosis
- Dietary modulation of microbial lipid metabolites and innate immunity in atherosclerosis 13:00~14:30
- Intermittent fasting as a nutritional intervention to modulate macrophage polarization for vascular health 13:20~13:40
- Targeting lipid peroxidation and ferroptosis to resolve inflammation in myocardial ischemia-reperfusion injury 13:40~14:00
- Panel Discussion 14:00~14:30
09. 10(Thu) 13:00~14:30 Room 2
Inflammation in ASCVD: From LDL Lowering to Immune Modulation
- LDL versus inflammation: what remains after aggressive lipid lowering? 13:00~13:18
- Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond 13:18~13:36
- Colchicine for secondary prevention in ASCVD 13:36~13:54
- Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets 13:54~14:12
- Panel Discussion 14:12~14:30
09. 10(Thu) 13:00~14:30 Room 3
From Biobank to Biology: Integrative Platforms for Cardiometabolic Discovery
09. 10(Thu) 13:00~14:30 Room 4
Publication Committee Session: JLA Award for Outstanding Article
09. 10(Thu) 14:30~16:00 Room 1
- TBD (Presentation Title) 14:30~14:40
- TBD (Presentation Title) 14:40~14:50
- TBD (Presentation Title) 14:50~15:00
- TBD (Presentation Title) 15:00~15:10
- TBD (Presentation Title) 15:10~15:20
- TBD (Presentation Title) 15:20~15:30
- TBD (Presentation Title) 15:30~15:40
- TBD (Presentation Title) 15:40~15:50
- TBD (Presentation Title) 15:50~16:00
09. 10(Thu) 14:30~16:00 Room 2
FH/Severe Dyslipidemia: Optimizing FH Management
09. 10(Thu) 14:30~16:00 Room 3
Optimizing Lipid-Lowering Strategies: Facing Challenges in Asian High-Risk Patients
- The race to the bottom: intensive LDL-C lowering in very high-risk Asian patients 14:30~14:50
- Combination therapy in high-risk patients: early vs stepwise approach 14:50~15:10
- Practical approaches to statin intolerance: from clinical trials to real-world solutions 15:10~15:30
- Panel Discussion 15:30~16:00
09. 10(Thu) 14:30~16:00 Room 4
Neurocardiometabolic Benefits of GLP1 RA and SGLT2 Inhibitors
09. 10(Thu) 16:10~17:40 Room 1
Real-world LDL-C Management: From Guideline to Prescription
- Choosing the right combination therapy: statin, ezetimibe, PCSK9 inhibitor, or beyond? 16:10~16:28
- Korean Fact Sheet: Current status of LDL-C control and cardiovascular risk 16:28~16:46
- Korean Fact Sheet: Real-world utilization of lipid lowering agents 16:46~17:04
- Why are LDL-C targets still unmet? common errors and practical solutions in the clinic 17:04~17:22
- Panel Discussion 17:22~17:40
09. 10(Thu) 16:10~17:40 Room 2
Comprehensive Lipid Management in East Asians: Integrating LDL-C Optimization, Residual Risk, and Genetic Factors
09. 10(Thu) 16:10~17:40 Room 3
Metabolic Regulators of Lipid Metabolism: From Mechanisms to Cardiovascular Outcomes
- Effects of SGLT2 inhibitors on lipid metabolism: mechanisms and clinical implications 16:10~16:30
- GLP-1 receptor agonists and lipid metabolism: beyond glycemic control 16:30~16:50
- Tirzepatide and cardiometabolic outcomes: implications of dual GLP-1/GIP agonism 16:50~17:10
- Panel Discussion 17:10~17:40
09. 10(Thu) 16:10~17:40 Room 4
Chronic Kidney Disease and Atherosclerosis
09. 11(Fri)
09. 11(Fri) 07:30~08:30 Room 1
09. 11(Fri) 07:30~08:30 Room 2
09. 11(Fri) 07:30~08:30 Room 3
09. 11(Fri) 07:30~08:30 Room 4
09. 11(Fri) 08:30~10:00 Room 1
- TBD (Presentation Title) 08:30~08:40
- TBD (Presentation Title) 08:40~08:50
- TBD (Presentation Title) 08:50~09:00
- TBD (Presentation Title) 09:00~09:10
- TBD (Presentation Title) 09:10~09:20
- TBD (Presentation Title) 09:20~09:30
- TBD (Presentation Title) 09:30~09:40
- TBD (Presentation Title) 09:40~09:50
- TBD (Presentation Title) 09:50~10:00
09. 11(Fri) 08:30~10:00 Room 2
New Frontiers in Lipid Lowering: Beyond Statins (New Drugs 1)
09. 11(Fri) 08:30~10:00 Room 3
Lipid-lowering Therapy in Complex Clinical Settings: HIV, Cancer, and Chronic Kidney Disease
09. 11(Fri) 08:30~10:00 Room 4
Bridging Cellular Physiology and Atherogenic Lipids
09. 11(Fri) 10:20~11:00 Room 1,2,3
09. 11(Fri) 11:00~11:40 Room 1,1,3
09. 11(Fri) 11:45~12:45 Room 1
09. 11(Fri) 11:45~12:45 Room 2
09. 11(Fri) 11:45~12:45 Room 5
09. 11(Fri) 12:45~13:45 Room 1
Sex-specific Lipid Biology and Cardiometabolic Risk across the Lifespan
- Genetic and epigenetic mechanisms underlying sex differences in cardiometabolic disease 12:45~13:00
- Early-onset dyslipidemia in young adults: screening strategies and lifetime ASCVD risk assessment 13:00~13:15
- Menopause and cardiometabolic transition: optimizing lipid management in midlife women 13:15~13:30
- Panel Discussion 13:30~13:45
09. 11(Fri) 12:45~13:45 Room 4
2026 KSoLA Awards for Scientific Excellence & Digital Health Media and Ethics
09. 11(Fri) 13:45~15:15 Room 1
Official Launch of the 2026 KSoLA Guidelines for the Management of Dyslipidemia
- Korean epidemiology and risk modifiers for establishing LDL-C goal strategies 13:45~14:03
- Practical algorithm for intensive lipid lowering therapy in the 2026 Korean guidelines 14:03~14:21
- Nutritional management and lifestyle modification tailored to the Korean dietary pattern 14:21~14:39
- Optimized lipid management for special populations 14:39~14:57
- Panel Discussion 14:57~15:15
09. 11(Fri) 13:45~15:15 Room 2
Residual Cardiovascular Risk Beyond LDL-C: The Emerging Role of Lipoprotein(a) in Asia
- Lipoprotein(a) in Korean patients: Real-world data, cardiovascular risk, and clinical implications 13:45~14:05
- Lipoprotein(a) and Coronary Atherosclerosis in Vietnam: Real-World Data and Emerging Cardiovascular Risk 14:05~14:25
- Measuring Lipoprotein(a) in clinical practice: Assay challenges, standardization, and interpretation 14:25~14:45
- Panel Discussion 14:45~15:15
09. 11(Fri) 13:45~15:15 Room 3
Evolution of High-risk Coronary Plaques: From Hemodynamics to Multimodality Assessment
- Evolution of vulnerable plaques: from natural history to preventive intervention 13:45~14:03
- High-risk plaque features on CCTA: identification and clinical implications 14:03~14:21
- Intravascular imaging of vulnerable plaques: insights from IVUS and OCT 14:21~14:39
- Coronary physiology and plaque vulnerability: linking function to risk 14:39~14:57
- Panel Discussion 14:57~15:15
09. 11(Fri) 13:45~15:15 Room 4
Metabolic Dysfunction, Fatty Liver, and Atherosclerosis
- Fatty liver and residual cardiovascular risk: epidemiology and clinical implications 13:45~14:05
- From lipotoxicity to atherosclerosis: MASLD/MetALD subtypes and cardiovascular risk 14:05~14:25
- Therapeutic strategies for cardiometabolic risk reduction in MASLD 14:25~14:45
- Panel Discussion 14:45~15:15
09. 11(Fri) 15:20~16:00 Room 1,2,3
09. 11(Fri) 16:10~17:40 Room 1
Intensive LDL-C Lowering in Primary Prevention
09. 11(Fri) 16:10~17:40 Room 2
Next-generation Lipid-lowering Therapies: CETP, APOC3, and ANGPTL3 Inhibition (New Drugs 2)
09. 11(Fri) 16:10~17:40 Room 3
Residual Cardiovascular Risk: Beyond LDL to Inflammation and Novel Targets
- Defining residual cardiovascular risk in the post-LDL era: unmet needs and mechanisms 16:10~16:28
- Targeting residual risk: Lp(a), triglyceride-rich lipoproteins, and inflammation 16:28~16:46
- Residual cardiovascular risk beyond LDL-C: the central role of ApoB lipoproteins 16:46~17:04
- Navigating residual thrombotic and inflammatory risk: lessons from AF and stable CAD management 17:04~17:22
- Panel Discussion 17:22~17:40
09. 11(Fri) 16:10~17:40 Room 4
Atherogenic Obesity: Beyond BMI to Lipid Dysfunction
09. 12(Sat)
09. 12(Sat) 07:50~08:50 Room 1
09. 12(Sat) 07:50~08:50 Room 4
09. 12(Sat) 08:50~10:20 Room 1
- TBD (Presentation Title) 08:50~09:00
- TBD (Presentation Title) 09:00~09:10
- TBD (Presentation Title) 09:10~09:20
- TBD (Presentation Title) 09:20~09:30
- TBD (Presentation Title) 09:30~09:40
- TBD (Presentation Title) 09:40~09:50
- TBD (Presentation Title) 09:50~10:00
- TBD (Presentation Title) 10:00~10:10
- TBD (Presentation Title) 10:10~10:20
09. 12(Sat) 08:50~10:20 Room 2
Contemporary Management of Residual Cardiovascular Risk in Asia
09. 12(Sat) 08:50~10:20 Room 3
Lp(a) beyond the Known: From Metabolic Pathways to Clinical Translation
09. 12(Sat) 08:50~10:20 Room 4
From Diversity to Action: Ethnicity, Genetics, and Closing the Treatment Gap in Asian Dyslipidemia
- Dyslipidemia across ethnicities in Malaysia: who is at risk, and who is being left behind? 08:50~09:10
- Genetic architecture of dyslipidemia and cardiovascular risk in East Asians: from monogenic variants to polygenic risk 09:10~09:30
- Epidemiological trends of dyslipidemia in Korea and their implications for Asian populations 09:30~09:50
- Panel Discussion 09:50~10:20
09. 12(Sat) 10:40~11:20 Room 1,2,3
09. 12(Sat) 11:20~12:00 Room 1,2,3
09. 12(Sat) 12:00~13:00 Room 2
09. 12(Sat) 13:00~14:00 Room 1
Hypertension, Lipids, and Vascular Aging: Integrated Cardiovascular Risk Management
09. 12(Sat) 13:00~14:00 Room 2
Beyond Stening: Contemporary Management of Residual Coronary Risk
09. 12(Sat) 13:00~14:00 Room 3
Integrated Cardiometabolic Risk Management in Diabetes
09. 12(Sat) 14:10~15:40 Room 1
Integrated Cardiovascular-kidney-metabolic Care: A Multidisciplinary Approach to CKM Syndrome
- Cardiologist perspective: implementing novel cardiometabolic therapies in CVD 14:10~14:30
- Nephrologist perspective: kidney protection strategies to reduce CKD progression and CV risk 14:30~14:50
- Endocrinologist perspective: optimizing combination therapy in complex CKM patients 14:50~15:10
- Panel Discussion 15:10~15:40
09. 12(Sat) 14:10~15:40 Room 2
AI-driven Innovations in Atherosclerosis
- AI-CVD: opportunistic testing of coronary calcium and beyond 14:10~14:28
- From physics to physiology: computational hemodynamics and coronary flow modeling in atherosclerosis 14:28~14:46
- Clinical applications of AI in coronary imaging 14:46~15:04
- AI-based retinomics: cardiovascular risk prediction using retinal imaging 15:04~15:22
- Panel Dicsussion 15:22~15:40
09. 12(Sat) 14:10~15:40 Room 3
Primary Prevention in Cardiovascular Disease: Beyond Traditional Risk Factors
09. 12(Sat) 14:10~15:40 Room 4
Lipid Metabolism Across Endocrine Disorders: From Mechanism to Clinical Practice
09. 12(Sat) 15:40~17:10 Room 1
Neural and Genetic Control of Eating Behavior and Cardiometabolic Health
09. 12(Sat) 15:40~17:10 Room 2
Bridging Europe and Korea in Dyslipidemia Management: Guidelines, Gaps, and Future Directions
09. 12(Sat) 15:40~17:10 Room 3
From Cells to Systems: Integrated Control of Cardiometabolic Health
- Non-inflammatory function of dendritic cell in the regulation of obesity-associated heart failure 15:40~15:58
- Hepatic lipotoxicity and fibrotic remodeling in metabolic liver disease 15:58~16:16
- From lipidomics to systems biology: decoding metabolic networks 16:16~16:34
- TBD 16:34~16:52
- Panel Discussion 16:52~17:10
09. 12(Sat) 15:40~17:10 Room 4
Environmental Cardiovascular Risk
